The management of chronic pain through mono-pharmacotherapy directed at G protein-coupled receptors using agonists such as morphine or clonidine sometimes results in adverse consequences, such as drug-induced tolerance or hypersensitivity, or prescription drug abuse. Opioid and adrenergic agonists produce analgesia synergistically at G protein-coupled receptors (GPCRs), which translates to significant pain relief with substantially lower doses and with significantly increased therapeutic indices. The objective of this application is to characterize the mechanisms underlying specific receptor subtype pairs with established synaptic localization. The central hypothesis of this application is that the mechanism underlying synergistic interactions between co-localized receptors differs from that underlying synergistic interactions between receptors residing in distinct locations. The proposed research will 1) determine how synergistic interactions occur between opioid receptor (OR) and alpha-2 adrenergic receptor (AR) agonists, and 2) examine the functional relationships between OR and AR with regards to nociceptive neurotransmitters.
Two Specific Aims comprise this application: 1. Establish the mechanism by which presynaptically co-localized GPCR pairs synergize. 2. Determine the mechanism by which presynaptic-postsynaptic GPCR pairs synergize. The mechanisms underlying synergistic interactions between GPCRs have been minimally investigated, have significant translational potential, and are, therefore, highly innovative. We and others have established that alpha 2 adrenergic and delta opioid receptors manifest powerful analgesic synergy when co-activated;more recently, we have demonstrated that co-localized alpha 2 adrenergic and delta opioid receptor subtypes can synergize in production of analgesic synergy and manifest this via cooperative inhibition of nociceptor transmitter release. The proposed research is expected to identify cellular signaling mechanisms operating in these spinal nociceptive terminals that give rise to synergy. Further, electrophysiological study of dorsal horn neurons will examine the intercellular mechanisms of drug action and interaction at the single cell level, specifically targeting two receptors that do not co-localize. The information gained from these studies may identify new therapeutic analgesic combinations and combination receptor targets leading toward reduction of dependence liabilities of analgesic treatments.
Opiates, like morphine and oxycontin, remain the most effective treatments to relieve moderate to severe persistent pain. However, opiates have several untoward effects that limit their use, for example constipation, tolerance and abuse liability. One approach to address the problems of opiate tolerance is the use of non-opiate pain relievers, like clonidine (an alpha 2 adrenergic drug), which are also accompanied by their own set of negative side effects. Synergistic combinations of very low doses (that don't provide much pain relief given by themselves) of an opiate and clonidine combined can provide full pain relief with reduced side effects. This project explores what cellular processes enable this synergistic pain relief in order to understand how to best take advantage of such therapeutic opportunities.
|Chabot-DorÃ©, A-J; Schuster, D J; Stone, L S et al. (2015) Analgesic synergy between opioid and Î±2 -adrenoceptors. Br J Pharmacol 172:388-402|
|Schuster, D J; Metcalf, M D; Kitto, K F et al. (2015) Ligand requirements for involvement of PKCÎµ in synergistic analgesic interactions between spinal Î¼ and Î´ opioid receptors. Br J Pharmacol 172:642-53|
|Chabot-DorÃ©, Anne-Julie; Millecamps, Magali; Naso, Lina et al. (2015) Dual allosteric modulation of opioid antinociceptive potency by Î±2A-adrenoceptors. Neuropharmacology 99:285-300|
|Stone, Laura S; German, Jonathan P; Kitto, Kelly F et al. (2014) Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects. PLoS One 9:e109903|
|Schuster, Daniel J; Kitto, Kelley F; Overland, Aaron C et al. (2013) Protein kinase CÎµ is required for spinal analgesic synergy between delta opioid and alpha-2A adrenergic receptor agonist pairs. J Neurosci 33:13538-46|
|Metcalf, Matthew D; Yekkirala, Ajay S; Powers, Michael D et al. (2012) The Ã½Ã½ opioid receptor agonist SNC80 selectively activates heteromeric Ã½Ã½-Ã½Ã½ opioid receptors. ACS Chem Neurosci 3:505-9|
|Fairbanks, Carolyn A; Stone, Laura S; Wilcox, George L (2009) Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. Pharmacol Ther 123:224-38|
|Overland, Aaron C; Kitto, Kelley F; Chabot-Dore, Anne-Julie et al. (2009) Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord. J Neurosci 29:13264-73|
|Riedl, Maureen S; Schnell, Stephen A; Overland, Aaron C et al. (2009) Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn. J Comp Neurol 513:385-98|
|Stein, Christoph; Clark, J David; Oh, Uhtaek et al. (2009) Peripheral mechanisms of pain and analgesia. Brain Res Rev 60:90-113|
Showing the most recent 10 out of 12 publications